Shares of Alector, Inc. (NASDAQ:ALEC – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the […]
Euclidean Capital LLC lifted its stake in shares of Alector, Inc. (NASDAQ:ALEC – Free Report) by 33.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,307,858 shares of the company’s stock after purchasing an additional 326,964 shares during the period. Alector comprises about 1.8% of […]
Hsbc Holdings PLC grew its position in Alector, Inc. (NASDAQ:ALEC – Free Report) by 64.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,807 shares of the company’s stock after buying an additional 14,472 shares during the quarter. Hsbc Holdings PLC’s holdings in […]
Acadian Asset Management LLC increased its holdings in shares of Alector, Inc. (NASDAQ:ALEC – Free Report) by 68.2% in the third quarter, Holdings Channel.com reports. The fund owned 153,266 shares of the company’s stock after buying an additional 62,155 shares during the quarter. Acadian Asset Management LLC’s holdings in Alector were worth $993,000 at the […]
The FDA has granted Breakthrough Therapy designation to latozinemab (AL001) for the treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN).